Tumor angiogenesis and stromal pathways and tumor cell DNA

The phrase Tumor angiogenesis and stromal pathways and tumor cell DNA does not refer to a single molecular target but rather a composite of three distinct therapeutic focal points in oncology. Tumor angiogenesis involves the formation of new blood vessels to supply nutrients to a growing tumor, primarily mediated by the VEGF pathway. Stromal pathways refer to the complex signaling between cancer cells and the surrounding tumor microenvironment, including fibroblasts and the extracellular matrix, often involving PDGF and FGF signaling. Tumor cell DNA represents the genetic blueprint of the malignancy, which is frequently targeted by chemotherapy or radiotherapy to induce apoptosis. Integrated therapeutic strategies often aim to hit all three areas to overcome resistance mechanisms and improve clinical outcomes in solid tumors.

This entry describes a multi-modal therapeutic approach rather than a single mechanism. It involves the simultaneous inhibition of vascular endothelial growth factor receptors (VEGFR) to block angiogenesis, targeting of fibroblast growth factor receptors (FGFR) and platelet-derived growth factor receptors (PDGFR) to disrupt stromal support, and the use of cytotoxic agents or radiation to induce direct DNA damage in tumor cells.